Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02425644
Recruitment Status : Completed
First Posted : April 24, 2015
Last Update Posted : September 4, 2019
Sponsor:
Information provided by (Responsible Party):
Actelion

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 16, 2019
Actual Study Completion Date : May 16, 2019